Abstract
Pharmacotherapy plays an important part in the overall management of patients with multiple sclerosis. Most therapies directed at altering the natural history of the underlying disease process are only partially effective or are controversial or experimental. However, many effective symptomatic therapies are available to the clinician. The action and uses of corticosteroids in multiple sclerosis are discussed, and approaches to the treatment of spasticity, paroxysmal disorders, bladder dysfunction, cerebellar ataxia, neurobehavioral manifestations, fatigue, and acute and chronic pain in patients with multiple sclerosis are examined.
MeSH terms
-
Acute Disease
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / adverse effects
-
Adrenal Cortex Hormones / pharmacology
-
Adrenal Cortex Hormones / therapeutic use*
-
Anxiety / complications
-
Anxiety / drug therapy
-
Baclofen / therapeutic use
-
Cerebellar Ataxia / complications
-
Cerebellar Ataxia / drug therapy
-
Chronic Disease
-
Dantrolene / therapeutic use
-
Depression / complications
-
Depression / drug therapy
-
Diazepam / therapeutic use
-
Dystonia / complications
-
Dystonia / drug therapy
-
Fatigue / complications
-
Fatigue / drug therapy
-
Humans
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / drug therapy*
-
Muscle Spasticity / complications
-
Muscle Spasticity / drug therapy
-
Pain / complications
-
Pain / drug therapy
-
Seizures / complications
-
Seizures / drug therapy
-
Time Factors
-
Urinary Bladder Diseases / complications
-
Urinary Bladder Diseases / drug therapy
Substances
-
Adrenal Cortex Hormones
-
Dantrolene
-
Baclofen
-
Diazepam